NBP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
NovaBridge Biosciences (NBP) is not a strong buy for a beginner, long-term investor at this time. While the stock has a positive analyst rating and a high price target, the company's financial performance is weak, with significant losses and no revenue growth. Technical indicators are mixed, with bearish moving averages and neutral RSI. Options data shows a lack of significant trading sentiment. Without strong positive catalysts or proprietary trading signals, holding off on investment is advisable.
The MACD is slightly positive at 0.012 and expanding, suggesting mild bullish momentum. However, the RSI at 44.978 is neutral, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Support and resistance levels indicate limited upward potential in the short term (Pivot: 3.24, R1: 3.392, S1: 3.087).
Analyst rating from H.C. Wainwright is positive, with a price target increase from $7 to $9, citing the potential of givastomig as a best-in-class bispecific antibody.
Weak financial performance in the latest quarter (2025/Q3), with no revenue growth and significant net income and EPS declines. No recent news or significant trading trends from insiders, hedge funds, or Congress.
In 2025/Q3, the company reported no revenue growth (0% YoY), a net income loss of -$6.83M (-66.68% YoY), and an EPS decline of -72.73% YoY. Gross margin remained at 0%.
H.C. Wainwright resumed coverage with a Buy rating and increased the price target from $7 to $9, citing the potential of givastomig in frontline immune chemotherapy combinations.
